デフォルト表紙
市場調査レポート
商品コード
1378760

コンパニオン診断市場レポート:製品・サービス、技術、適応症、エンドユーザー、地域別、2023-2028年

Companion Diagnostics Market Report by Product & Service, Technology (Immunohistochemistry, Polymerase Chain Reaction, In-situ Hybridization, Real-time PCR, Gene Sequencing, and Others), Indication, End User, and Region 2023-2028

出版日: | 発行: IMARC | ページ情報: 英文 144 Pages | 納期: 2~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=160.11円
コンパニオン診断市場レポート:製品・サービス、技術、適応症、エンドユーザー、地域別、2023-2028年
出版日: 2023年11月02日
発行: IMARC
ページ情報: 英文 144 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

概要

世界のコンパニオン診断の市場規模は、2022年に59億米ドルに達しました。今後、IMARC Groupは、同市場が2028年までに133億米ドルに達し、2022年から2028年の間に14.5%の成長率(CAGR)を示すと予測しています。がんの有病率の増加、個別化医療に対する需要の急増、次世代シーケンシング(NGS)のような継続的な技術進歩は、市場を牽引する主な要因のいくつかです。

コンパニオン診断は、医師が最も効果的な治療計画を決定するのに役立つ医療検査です。これらの検査は、患者の組織や血液サンプルから特定のバイオマーカーを同定し、患者が特定の薬物や治療から恩恵を受ける可能性が高いかどうかを示すように設計されています。また、患者の詳細な生物学的プロファイルと作用機序(MOA)を分析し、医療専門家が薬の潜在的な副作用を理解するのを助けます。コンパニオン診断は、最適な治療計画を決定するために、遺伝子構成など、それぞれの患者固有の特徴を考慮するため、個別化医療において広く使用されています。これに加えて、がん患者の特定の遺伝子変異やC型肝炎患者のバイオマーカーを検査するために使用されることが増えています。これにより、医師は個々の患者に合わせた治療を行い、治療が成功する可能性を高め、副作用のリスクを減らすことができます。

コンパニオン診断市場の動向:

世界中で様々な種類のがんが増加しており、より効果的で的を絞ったがん治療に対する需要が高まっています。コンパニオン診断は、特定のがん治療から利益を得る可能性が最も高い患者を特定するのに役立ち、その結果、患者の転帰を改善します。さらに、各患者の特性に合わせた個別化医薬品の需要が高まっていることも、同市場に有利な見通しをもたらしています。これと同時に、多くの感染症、心血管疾患、神経疾患、炎症性疾患の治療に標的薬や治療法が広く採用されていることも、もう一つの大きな成長促進要因として作用しています。これに加えて、コンパニオン診断に対する規制状況が良好で、米国食品医薬品局(FDA)などの規制当局から承認を受ける検査が増加していること、世界中で臨床試験の数が拡大していることも、市場の成長を強化しています。さらに、次世代シークエンシング(NGS)やリキッドバイオプシーの登場など、診断技術の進歩が進み、以前は検出が困難であったバイオマーカーの同定が可能になったことも、市場の成長に寄与しています。このほか、革新的なゲノム技術の開拓により、治療方針の決定に利用できる遺伝子変異やその他のバイオマーカーの同定が可能になったことも、市場の成長を後押ししています。その他にも、医薬品開発におけるバイオマーカー利用の増加、精密医療への広範な投資、コンパニオン診断の利点に関する消費者の意識の高まりなどが、市場に有益な成長機会をもたらしています。

本レポートで扱う主な質問

  • 2022年のコンパニオン診断世界市場規模は?
  • 2023-2028年のコンパニオン診断世界市場の予想成長率は?
  • COVID-19がコンパニオン診断の世界市場に与えた影響は?
  • コンパニオン診断の世界市場を牽引する主要因は?
  • コンパニオン診断世界市場の製品・サービス別区分は?
  • コンパニオン診断世界市場の技術別区分は?
  • コンパニオン診断世界市場の適応症別区分は?
  • コンパニオン診断世界市場のエンドユーザー別区分は?
  • コンパニオン診断世界市場の主要地域は?
  • コンパニオン診断世界市場の主要プレイヤー/企業は?

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 コンパニオン診断の世界市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳:製品・サービス別

  • アッセイ、キット、試薬
    • 市場動向
    • 市場予測
  • ソフトウェアとサービス
    • 市場動向
    • 市場予測

第7章 市場内訳:技術別

  • 免疫組織化学(IHC)
    • 市場動向
    • 市場予測
  • ポリメラーゼ連鎖反応(PCR)
    • 市場動向
    • 市場予測
  • インサイチュハイブリダイゼーション(ISH)
    • 市場動向
    • 市場予測
  • リアルタイムPCR(RT-PCR)
    • 市場動向
    • 市場予測
  • 遺伝子シーケンス
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第8章 市場内訳:適応症別

  • がん
    • 市場動向
    • 主要タイプ
      • 肺がん
      • 乳がん
      • 大腸がん
      • 胃がん
      • 黒色腫
      • その他
    • 市場予測
  • 神経疾患
    • 市場動向
    • 市場予測
  • 感染症
    • 市場動向
    • 市場予測
  • 循環器疾患
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第9章 市場内訳:エンドユーザー別

  • 製薬・バイオ製薬企業
    • 市場動向
    • 市場予測
  • リファレンスラボ
    • 市場動向
    • 市場予測
  • 調査受託機関
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第10章 市場内訳:地域別

  • 北米
    • 米国
      • 市場動向
      • 市場予測
    • カナダ
      • 市場動向
      • 市場予測
  • アジア太平洋
    • 中国
      • 市場動向
      • 市場予測
    • 日本
      • 市場動向
      • 市場予測
    • インド
      • 市場動向
      • 市場予測
    • 韓国
      • 市場動向
      • 市場予測
    • オーストラリア
      • 市場動向
      • 市場予測
    • インドネシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 欧州
    • ドイツ
      • 市場動向
      • 市場予測
    • フランス
      • 市場動向
      • 市場予測
    • 英国
      • 市場動向
      • 市場予測
    • イタリア
      • 市場動向
      • 市場予測
    • スペイン
      • 市場動向
      • 市場予測
    • ロシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • ラテンアメリカ
    • ブラジル
      • 市場動向
      • 市場予測
    • メキシコ
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 中東・アフリカ地域
    • 市場動向
    • 市場内訳:国別
    • 市場予測

第11章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第14章 価格分析

第15章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Abbott Laboratories
    • Agilent Technologies
    • BioMerieux
    • Danaher Corporation
    • Roche Holding AG
    • Myriad Genetics Inc.
    • Siemens Healthcare
    • Thermo Fisher Scientific Inc.
図表

List of Figures

  • Figure 1: Global: Companion Diagnostics Market: Major Drivers and Challenges
  • Figure 2: Global: Companion Diagnostics Market: Sales Value (in Billion US$), 2017-2022
  • Figure 3: Global: Companion Diagnostics Market: Breakup by Product & Service (in %), 2022
  • Figure 4: Global: Companion Diagnostics Market: Breakup by Technology (in %), 2022
  • Figure 5: Global: Companion Diagnostics Market: Breakup by Indication (in %), 2022
  • Figure 6: Global: Companion Diagnostics Market: Breakup by End User (in %), 2022
  • Figure 7: Global: Companion Diagnostics Market: Breakup by Region (in %), 2022
  • Figure 8: Global: Companion Diagnostics Market Forecast: Sales Value (in Billion US$), 2023-2028
  • Figure 9: Global: Companion Diagnostics (Assays, Kits and Reagents) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 10: Global: Companion Diagnostics (Assays, Kits and Reagents) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 11: Global: Companion Diagnostics (Software and Services) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 12: Global: Companion Diagnostics (Software and Services) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 13: Global: Companion Diagnostics (Immunohistochemistry) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 14: Global: Companion Diagnostics (Immunohistochemistry) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 15: Global: Companion Diagnostics (Polymerase Chain Reaction) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 16: Global: Companion Diagnostics (Polymerase Chain Reaction) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 17: Global: Companion Diagnostics (In-situ Hybridization) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 18: Global: Companion Diagnostics (In-situ Hybridization) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 19: Global: Companion Diagnostics (Real-time PCR) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 20: Global: Companion Diagnostics (Real-time PCR) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 21: Global: Companion Diagnostics (Gene Sequencing) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 22: Global: Companion Diagnostics (Gene Sequencing) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 23: Global: Companion Diagnostics (Other Technologies) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 24: Global: Companion Diagnostics (Other Technologies) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 25: Global: Companion Diagnostics (Cancer) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 26: Global: Companion Diagnostics (Cancer) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 27: Global: Companion Diagnostics (Neurological Diseases) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 28: Global: Companion Diagnostics (Neurological Diseases) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 29: Global: Companion Diagnostics (Infectious Diseases) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 30: Global: Companion Diagnostics (Infectious Diseases) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 31: Global: Companion Diagnostics (Cardiovascular Diseases) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 32: Global: Companion Diagnostics (Cardiovascular Diseases) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 33: Global: Companion Diagnostics (Other Indications) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 34: Global: Companion Diagnostics (Other Indications) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 35: Global: Companion Diagnostics (Pharmaceutical & Biopharmaceutical Companies) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 36: Global: Companion Diagnostics (Pharmaceutical & Biopharmaceutical Companies) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 37: Global: Companion Diagnostics (Reference Laboratories) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 38: Global: Companion Diagnostics (Reference Laboratories) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 39: Global: Companion Diagnostics (Contract Research Organizations) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 40: Global: Companion Diagnostics (Contract Research Organizations) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 41: Global: Companion Diagnostics (Other End Users) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 42: Global: Companion Diagnostics (Other End Users) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 43: North America: Companion Diagnostics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 44: North America: Companion Diagnostics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 45: United States: Companion Diagnostics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 46: United States: Companion Diagnostics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 47: Canada: Companion Diagnostics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 48: Canada: Companion Diagnostics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 49: Asia Pacific: Companion Diagnostics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 50: Asia Pacific: Companion Diagnostics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 51: China: Companion Diagnostics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 52: China: Companion Diagnostics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 53: Japan: Companion Diagnostics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 54: Japan: Companion Diagnostics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 55: India: Companion Diagnostics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 56: India: Companion Diagnostics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 57: South Korea: Companion Diagnostics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 58: South Korea: Companion Diagnostics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 59: Australia: Companion Diagnostics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 60: Australia: Companion Diagnostics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 61: Indonesia: Companion Diagnostics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 62: Indonesia: Companion Diagnostics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 63: Others: Companion Diagnostics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 64: Others: Companion Diagnostics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 65: Europe: Companion Diagnostics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 66: Europe: Companion Diagnostics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 67: Germany: Companion Diagnostics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 68: Germany: Companion Diagnostics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 69: France: Companion Diagnostics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 70: France: Companion Diagnostics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 71: United Kingdom: Companion Diagnostics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 72: United Kingdom: Companion Diagnostics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 73: Italy: Companion Diagnostics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 74: Italy: Companion Diagnostics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 75: Spain: Companion Diagnostics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 76: Spain: Companion Diagnostics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 77: Russia: Companion Diagnostics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 78: Russia: Companion Diagnostics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 79: Others: Companion Diagnostics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 80: Others: Companion Diagnostics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 81: Latin America: Companion Diagnostics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 82: Latin America: Companion Diagnostics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 83: Brazil: Companion Diagnostics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 84: Brazil: Companion Diagnostics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 85: Mexico: Companion Diagnostics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 86: Mexico: Companion Diagnostics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 87: Others: Companion Diagnostics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 88: Others: Companion Diagnostics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 89: Middle East and Africa: Companion Diagnostics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 90: Middle East and Africa: Companion Diagnostics Market: Breakup by Country (in %), 2022
  • Figure 91: Middle East and Africa: Companion Diagnostics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 92: Global: Companion Diagnostics Industry: SWOT Analysis
  • Figure 93: Global: Companion Diagnostics Industry: Value Chain Analysis
  • Figure 94: Global: Companion Diagnostics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Companion Diagnostics Market: Key Industry Highlights, 2022 and 2028
  • Table 2: Global: Companion Diagnostics Market Forecast: Breakup by Product & Service (in Million US$), 2023-2028
  • Table 3: Global: Companion Diagnostics Market Forecast: Breakup by Technology (in Million US$), 2023-2028
  • Table 4: Global: Companion Diagnostics Market Forecast: Breakup by Indication (in Million US$), 2023-2028
  • Table 5: Global: Companion Diagnostics Market Forecast: Breakup by End User (in Million US$), 2023-2028
  • Table 6: Global: Companion Diagnostics Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 7: Global: Companion Diagnostics Market Structure
  • Table 8: Global: Companion Diagnostics Market: Key Players
目次
Product Code: SR112023A2548

Abstract

The global companion diagnostics market size reached US$ 5.9 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 13.3 Billion by 2028, exhibiting a growth rate (CAGR) of 14.5% during 2022-2028. The increasing prevalence of cancer, the surging demand for personalized medicine, and ongoing technological advancements, such as next-generation sequencing (NGS), represent some of the key factors driving the market.

Companion diagnostics are medical tests that help physicians determine the most effective treatment plan. These tests are designed to identify specific biomarkers in a patient's tissue or blood sample, indicating whether the patient will likely benefit from a particular drug or therapy. They also analyze the detailed biological profile and the mechanism of action (MOA) of patients and assist medical professionals in understanding the potential side effects of medications. Companion diagnostics are widely used across personalized medicines as it considers each patient's unique characteristics, such as their genetic makeup, to determine the best treatment plan. In addition to this, they are increasingly used for testing specific genetic mutations in cancer patients or biomarkers in patients with hepatitis C. This helps physicians tailor treatments to individual patients, improving the likelihood of successful outcomes and reducing the risk of side effects.

Companion Diagnostics Market Trends:

The rising instances of various kinds of cancer across the globe are impelling the demand for more effective and targeted cancer treatments, which is primarily driving the market growth. Companion diagnostics help identify patients who are most likely to benefit from specific cancer therapies, resulting in better patient outcomes. Moreover, the growing demand for personalized medicines tailored to each patient's unique characteristics is creating a favorable outlook for the market. Concurrent with this, the widespread adoption of targeted drugs and therapies for treating numerous infectious, cardiovascular, neurological, and inflammatory conditions is acting as another significant growth-inducing factor. In addition to this, the favorable regulatory landscape for companion diagnostics, with an increasing number of tests receiving approval from governing authorities such as the United States Food and Drug Administration (US FDA), and the expanding number of clinical trials around the world are strengthening the market growth. Furthermore, ongoing advancements in diagnostic technologies, such as the emergence of next-generation sequencing (NGS) and liquid biopsy, which have allowed identifying biomarkers that were formerly difficult to detect, are contributing to the market growth. Besides this, the development of innovative genomic technologies, which have enabled the identification of genetic mutations and other biomarkers that can be used to guide treatment decisions, is fueling the market growth. Other factors, such as the rising use of biomarkers in drug development, extensive investments in precision medicine, and the escalating consumer awareness regarding the benefits of companion diagnostics, are presenting remunerative growth opportunities for the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global companion diagnostics market report, along with forecasts at the global, regional, and country levels from 2023-2028. Our report has categorized the market based on product & service, technology, indication, and end user.

Product & Service Insights:

Assays, Kits and Reagents

Software and Services

The report has provided a detailed breakup and analysis of the companion diagnostics market based on the product & service. This includes assays, kits and reagents, and software and services. According to the report, assays, kits, and reagents represented the largest segment.

Technology Insights:

Immunohistochemistry (IHC)

Polymerase Chain Reaction (PCR)

In-situ Hybridization (ISH)

Real-time PCR (RT-PCR)

Gene Sequencing

Others

A detailed breakup and analysis of the companion diagnostics market based on technology has also been provided in the report. This includes immunohistochemistry (IHC), polymerase chain reaction (PCR), in-situ hybridization (ISH), real-time PCR (RT-PCR), gene sequencing, and others. According to the report, polymerase chain reaction (PCR) accounted for the largest market share.

Indication Insights:

Cancer

Lung Cancer

Breast Cancer

Colorectal Cancer

Gastric Cancer

Melanoma

Others

Neurological Diseases

Infectious Diseases

Cardiovascular Diseases

Others

The report has provided a detailed breakup and analysis of the companion diagnostics market based on the indication. This includes cancer (lung cancer, breast cancer, colorectal cancer, gastric cancer, melanoma, and others), neurological diseases, infectious diseases, cardiovascular diseases, and others. According to the report, cancer represented the largest segment.

End User Insights:

Pharmaceutical & Biopharmaceutical Companies

Reference Laboratories

Contract Research Organizations

Others

A detailed breakup and analysis of the companion diagnostics market based on the end user has also been provided in the report. This includes pharmaceutical & biopharmaceutical companies, reference laboratories, contract research organizations, and others. According to the report, pharmaceutical & biopharmaceutical companies accounted for the largest market share.

Regional Insights:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for companion diagnostics. Some of the factors driving the North America companion diagnostics market included the growing prevalence of cancer, the rising adoption of personalized medicines and targeted therapies, and significant advancements in next-generation sequencing (NGS).

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global companion diagnostics market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Abbott Laboratories, Agilent Technologies, BioMerieux, Danaher Corporation, Roche Holding AG, Myriad Genetics Inc., Siemens Healthcare, and Thermo Fisher Scientific Inc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report

  • 1. What was the size of the global companion diagnostics market in 2022?
  • 2. What is the expected growth rate of the global companion diagnostics market during 2023-2028?
  • 3. What has been the impact of COVID-19 on the global companion diagnostics market?
  • 4. What are the key factors driving the global companion diagnostics market?
  • 5. What is the breakup of the global companion diagnostics market based on the product & service?
  • 6. What is the breakup of the global companion diagnostics market based on the technology?
  • 7. What is the breakup of the global companion diagnostics market based on the indication?
  • 8. What is the breakup of the global companion diagnostics market based on the end user?
  • 9. What are the key regions in the global companion diagnostics market?
  • 10. Who are the key players/companies in the global companion diagnostics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Companion Diagnostics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product & Service

  • 6.1 Assays, Kits and Reagents
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Software and Services
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Technology

  • 7.1 Immunohistochemistry (IHC)
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Polymerase Chain Reaction (PCR)
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 In-situ Hybridization (ISH)
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Real-time PCR (RT-PCR)
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Gene Sequencing
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Others
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast

8 Market Breakup by Indication

  • 8.1 Cancer
    • 8.1.1 Market Trends
    • 8.1.2 Major Types
      • 8.1.2.1 Lung Cancer
      • 8.1.2.2 Breast Cancer
      • 8.1.2.3 Colorectal Cancer
      • 8.1.2.4 Gastric Cancer
      • 8.1.2.5 Melanoma
      • 8.1.2.6 Others
    • 8.1.3 Market Forecast
  • 8.2 Neurological Diseases
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Infectious Diseases
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Cardiovascular Diseases
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Others
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Pharmaceutical & Biopharmaceutical Companies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Reference Laboratories
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Contract Research Organizations
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Others
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Abbott Laboratories
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Agilent Technologies
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 BioMerieux
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Danaher Corporation
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Roche Holding AG
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 SWOT Analysis
    • 15.3.6 Myriad Genetics Inc.
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Siemens Healthcare
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Thermo Fisher Scientific Inc.
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis